Start here if you're new
what it is
Amicus sells rare-disease medicines for Fabry and Pompe disease in more than 40 countries.
how it gets paid
Last year Amicus Therapeutics made $634M in revenue.
why it's growing
Revenue grew 20.0% last year. The $449M revenue line matters most. It shows the drugs are selling.
what just happened
Amicus posted $449M in quarterly revenue, but EPS stayed at -$0.09.
At a glance
B+ balance sheet — decent shape, but not bulletproof
45/100 earnings predictability — expect surprises
-$0.16 fy2024 eps est
$528M fy2024 rev est
8.1% operating margin
xvary composite: 55/100 — below average
What they do
Amicus sells rare-disease medicines for Fabry and Pompe disease in more than 40 countries.
You are not buying toothpaste. Amicus sells 2 rare-disease drugs, and that makes every approval count. Galafold is approved in more than 40 countries, while Pombiliti plus Opfolda is approved in 7, so the company has reach where patient pools are tiny. Gross margin was 89.7%, which means most of each sales dollar survived after making the drugs.
How they make money
$634M
annual revenue · their business grew +20.0% last year
total revenue
$634M
+20.0%
The products that matter
Fabry disease treatment
Galafold
$~380M · lead product
this is still the anchor product, with roughly $380M in revenue against a company-wide $528M revenue estimate. if the deal disappeared, this is the first number you'd care about.
core asset
Pompe disease therapy
Pombiliti + Opfolda
$~254M · growth engine
the current feed shows roughly $254M here with growth of about 30%. treat the number as directional, but the message is clear: this is the second commercial leg under the BioMarin deal.
second leg
transaction outcome
BioMarin acquisition
$14.50 cash · Q2 2026 target close
not a product, but it is the economic reality for you now. a stock at $14.31 with a $14.50 takeout is trading on closing risk, not pipeline imagination.
the real trade
Key numbers
$634M
annual revenue
Revenue is the money coming in. $634M says the business is real, while the $4.8B buyout says it is still small enough to get swallowed.
89.7%
gross margin
Gross margin is what stays after making the drug. 89.7% means Amicus keeps most of each sales dollar before overhead.
$14.50
buyout price
BioMarin's offer caps the stock story at a known number. You are playing for $0.19 from the current $14.31, not a moonshot.
$434M
long-term debt
Debt is borrowed money. $434M is manageable next to $634M of annual sales, but it still eats flexibility.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 25 / 100
- long-term debt $434M (9% of capital)
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for FOLD right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Amicus posted $449M in quarterly revenue, but EPS stayed at -$0.09.
Sales jumped 166% from the prior year, and gross margin was 89.7%. The quarter still lost money.
$159M
revenue
-$0.09
eps
89.7%
gross margin
revenue
The $449M revenue line matters most. It shows the drugs are selling, while the -$0.09 EPS says profit is still the missing piece.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is the BioMarin acquisition not closing on the expected timeline. when only 1.3% upside is left, you do not need disaster for the math to get worse — delay is enough.
med
deal break risk
If the $14.50 cash acquisition fails, the stock stops being a spread and goes back to trading on standalone biotech fundamentals — growth, margins, concentration, and execution.
Current page risk framing already implies downside of roughly 30–40% below the deal price if that happens.
med
regulatory timing slippage
The company is targeting a Q2 2026 close. If approvals slip, your 1.3% spread has to cover more time, more headlines, and more uncertainty.
Small absolute upside becomes less attractive the longer the calendar stretches.
med
sale-process litigation
Law firms are investigating whether the board met its duties and whether $14.50 is fair. Most of these cases settle into paperwork. some create delays. with this little spread, delay matters.
Even without killing the deal, added friction can widen the spread and pressure the stock.
med
standalone concentration
If you ever have to underwrite the business again, you are looking at a company with roughly $528M of estimated revenue concentrated in two rare-disease therapies, including Galafold at about $380M.
That is not broad diversification. every product setback would matter fast.
You are risking a stock that sits 1.3% below cash consideration for a downside profile that the current page already frames as far larger if the deal breaks.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
Q2 2026 close window
This is the deadline that turns the current 1.3% spread into actual cash. if the date slips, the annualized appeal slips with it.
metric
the spread to $14.50
At $14.31 versus a $14.50 takeout, the spread is only 1.3%. that number tells you how much optimism is already priced in.
risk
any sign approvals are taking longer
In a normal growth stock, waiting can be fine. in a merger spread this thin, time is not neutral.
trend
whether quarterly noise stays irrelevant
Q4 2025 missed EPS estimates, but the stock's real job now is to stay attached to the transaction. if earnings start changing deal sentiment, that would be new.
Analyst rankings
earnings predictability
45 / 100
in human-speak, the quarterly numbers can still jump around more than you'd like.
balance sheet grade
B+
Good enough to function, not so strong that the standalone story would feel risk-free if the deal vanished.
price stability
25 / 100
This has traded like a biotech, not a utility. the signed deal calms that down, but it doesn't erase the history.
source: institutional data
Institutional activity
institutional ownership data for FOLD is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$14
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive